Alivus Life Sciences Limited

BSE: 543322 NSE: GLS
Alivus Life Sciences Limited - pharma in Solapur, Maharashtra, India. FY 2026 financials & compliance.
CIN L74900PN2011PLC139963 Incorporated 23 June 2011 ROC Pune HQ Solapur, Maharashtra, India
Active Listed - NSE: GLS · BSE: 543322 Public Limited Company pharma
Data last updated
Market Cap
₹16,766 Cr
ALIVUS · NSE
Share Price
₹1,345.50
-1.47% today
Revenue
₹2,552 Cr
FY 2025-26 · +4.5% YoY
EBITDA
₹772 Cr
Margin 30.2%
Net Profit
₹550 Cr
FY 2025-26 · +14.9% YoY
P/E (TTM)
15.2x
P/B 2.9x
ROE
18.4%
ROCE 23.9%
Debt / Equity
0.02
Interest cover 0.8x

About Alivus Life Sciences Limited

Data last updated: 28 September 2026

Alivus Life Sciences Limited is a public limited company based in Solapur, Maharashtra, India, a subsidiary of Nirma Limited. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 23 June 2011, the company has been in operation for over 15 years.

Registered with ROC Pune under CIN L74900PN2011PLC139963. Listed on BSE: 543322 and NSE: GLS.

Capital: an authorised share capital of ₹46 Cr and a paid-up capital of ₹24.55 Cr. Formerly known as Zorg Laboratories Private Limited and Glenmark Life Sciences Private Limited. It is led by directors including Yasir Yusufali Rawjee and Taruvai Laxminarayanan Easwar.

Last AGM: 08 September 2025. Financial statements filed for year ended 31 March 2025. Office: Solapur, Maharashtra.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹2,551.83 Cr, a growth of 6.91% compared to the previous year. The net worth stands at ₹3,332.14 Cr (up 18.27% YoY). Total assets are valued at ₹3,425.05 Cr (up 18.41% YoY).

The company has a workforce of approximately 2,021 employees as per the latest available data. It operates as a subsidiary of Nirma Limited.

The company is associated with 2 brands - Glenmark Life Sciences, Alivus.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website glenmarklifesciences.com.

Company Details of Alivus Life Sciences Limited
CIN L74900PN2011PLC139963
Registration Number 139963
Incorporation Date 23 June 2011
ROC Pune
Listing Status Listed (BSE: 543322, NSE: GLS)
Company Status Active
Date of Last AGM 08 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Nirma Limited
Compliance Status Active Compliant
Key People
Yasir Yusufali Rawjee Managing Director Vinod Naik Whole-Time Director Taruvai Laxminarayanan Easwar Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    glenmarklifesciences.com
  • Social Media
  • Registered Address
    Plot No 170 – 172 Chandramouli Industrial Estate Mohol Ba, Zarpeth, Solapur, Maharashtra, India – 413213
  • Industry
    Pharma, API Manufacturers
Company report
Alivus Life Sciences Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Alivus Life Sciences Limited report

Financials, compliance, directors, charges, ownership and filings for Alivus Life Sciences Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Alivus Life Sciences Limited

Alivus Life Sciences Limited has undergone 2 name changes throughout its history. The company was previously known as Zorg Laboratories Private Limited, and Glenmark Life Sciences Private Limited. The current legal name is Alivus Life Sciences Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Alivus Life Sciences Limited Current
Zorg Laboratories Private Limited Previous
Glenmark Life Sciences Private Limited Previous

CIN History of Alivus Life Sciences Limited

Alivus Life Sciences Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74900PN2011PLC139963, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L74900PN2011PLC139963 Current
U74900PN2011PTC139963 Previous
U74900PN2011PLC139963 Previous

Associated Brands with Alivus Life Sciences Limited

Alivus Life Sciences Limited operates two associated brands: Glenmark Life Sciences and Alivus. These brands represent Alivus Life Sciences Limited's diversified market presence and brand portfolio.

Brand Description Website
Glenmark Life Sciences
API manufacturing is provided by the CDMO in India. glenmarklifesciences.com
Alivus
High-value APIs are developed and manufactured for global partners. alivus.com

Competitors & Alternatives of Alivus Life Sciences Limited

Brands and companies operating in the same space as Alivus Life Sciences Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.

Competitor Description Location Founded
Laurus Labs Laurus Labs Pharmaceutical and biotechnology company Hyderabad, India, India 2005
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured. Indore, India, India 2002
Beijing Biostar Technologies Beijing Biostar Technologies APIs, intermediates, and biochemical reagents are developed and manufactured. Beijing, China, China 2002
Sterling Pharma Solutions Sterling Pharma Solutions Contract development, manufacturing, and analytical services for APIs are offered. Dudley, United Kingdom, United Kingdom 2016
Provepharm Life Solutions Provepharm Life Solutions APIs and drug products are developed and valorized in pharmaceuticals. Marseille, France, France 1998
Hikal Hikal APIs and intermediates are produced via custom synthesis and research. Mumbai, India, India 1988
Snapdragon Chemistry Snapdragon Chemistry Drug discovery and development service provider Cambridge, United States, United States 2014
SeQuent SeQuent APIs are developed and manufactured for therapeutic areas. Bengaluru, India, India 2002
Jubilant Pharma Jubilant Pharma Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. Noida, India, India 1978

Business Activity of Alivus Life Sciences Limited

Alivus Life Sciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Alivus Life Sciences Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Alivus Life Sciences Limited

Alivus Life Sciences Limited is audited by Walker Chandiok & Co LLP for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
Walker Chandiok & Co LLP Locked Locked Locked
Premium access

Complete auditor history for Alivus Life Sciences Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Alivus Life Sciences Limited

Alivus Life Sciences Limited is currently managed by 7 directors, with 14 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Yasir Yusufali Rawjee Managing Director 26 Sep 2019 7 Years 0 Months Current
Taruvai Laxminarayanan Easwar Director 08 Mar 2021 5 Years 6 Months Current
Manju Agarwal
Also directs: Gulf Oil Lubricants India Limited, Gocl Corporation Limited, Polycab India Limited and 5 more
Director 08 Mar 2021 5 Years 6 Months Current
Vinod Naik Whole-Time Director 21 Oct 2022 3 Years 11 Months Current
Savan Rashmikant Godiawala
Also directs: Carysil Limited, Elecon Engineering Company Limited, Arvind Smartspaces Limited and 2 more
Director 25 Apr 2024 2 Years 5 Months Current
Kaushikbhai Nandubhai Patel
Also directs: Nuvoco Vistas Corporation Limited, Nirma Limited
Director 06 Mar 2024 2 Years 6 Months Current
Showing 6 of 7 current directors. View all directors

Financials of Alivus Life Sciences Limited FY 2025-26 filings available

Alivus Life Sciences Limited reported revenue of ₹2,551.83 Cr (up 6.91% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹2,552 Cr
+6.9% YoY
EBITDA
₹772 Cr
+13.0% YoY
Profit After Tax
₹550 Cr
+14.9% YoY
Net Worth
₹3,332 Cr
+18.3% YoY
Total Assets
₹3,425 Cr
+18.4% YoY
Total Debt
₹56.77 Cr
+0.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,5522,3872,2832,1612,1231,8851,537
Revenue growth+4.5%+5.9%+5.9%+0.8%+16.5%+21.5%+66.8%
EBITDA772683674642616591472
EBITDA margin+30.2%+28.6%+29.5%+29.7%+29.0%+31.4%+30.7%
Profit before tax751654631629565471421
Net profit550478471467419352314
Net profit margin+21.5%+20.0%+20.7%+21.6%+19.8%+18.7%+20.4%
EPS (₹)45.9939.6338.4338.1134.17358.761,597.44
Balance sheet
Total assets3,4252,8932,3652,1652,057753402
Net worth3,3322,8172,3322,1382,054753402
Total debt56.7756.6117.1519.362.880.000.02
Cash & bank2.1371.2430230951211610.00
Net working capital1,3691,3931,4801,3561,382178(147)
Cash flow
Cash from operations565392414306598388195
Cash from investing(570)(616)(116)(147)(122)(68.73)(50.52)
Cash from financing(64.34)(6.23)(279)(388)(78.80)(214)(137)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue640689673588602650642507
Revenue growth (YoY)+6.4%+6.1%+4.8%+16.0%+2.3%+21.1%+12.1%-14.9%
Other income22.4022.7813.9314.728.9910.0910.468.53
Total expenses429475467409430451452373
EBITDA212215206179172198190134
EBITDA margin+33.1%+31.1%+30.6%+30.5%+28.6%+30.6%+29.6%+26.5%
Depreciation20.5920.2019.6618.4417.0615.9715.1615.09
Interest1.311.311.491.321.251.260.460.34
Profit before tax212216198174163191185127
Tax52.1453.1448.1344.1141.4549.4348.1932.14

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 28 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue640689673588602650642507
Revenue growth (YoY)+6.4%+6.1%+4.8%+16.0%+2.3%+21.1%+12.1%-14.9%
Other income22.4022.7813.9314.728.9910.0910.468.53
Total expenses429475467409430451452373
EBITDA212215206179172198190134
EBITDA margin+33.1%+31.1%+30.6%+30.5%+28.6%+30.6%+29.6%+26.5%
Depreciation20.5920.2019.6618.4417.0615.9715.1615.09
Interest1.311.311.491.321.251.260.460.34
Profit before tax212216198174163191185127
Tax52.1453.1448.1344.1141.4549.4348.1932.14
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,5522,3872,2832,1612,1231,8851,537
Revenue growth+4.5%+5.9%+5.9%+0.8%+16.5%+21.5%+66.8%
Other income60.4134.5712.0428.9614.700.8111.99
Total expenses1,7801,7041,6091,5191,5071,2941,065
Employee cost272252258180169149142
EBITDA772683674642616591472
EBITDA margin+30.2%+28.6%+29.5%+29.7%+29.0%+31.4%+30.7%
Depreciation75.3660.6153.4542.0937.8833.3929.37
Interest5.372.411.550.5527.9687.5533.52
Profit before tax751654631629565471421
Tax187168160162146119108
Net profit550478471467419352314
Net profit margin+21.5%+20.0%+20.7%+21.6%+19.8%+18.7%+20.4%
EPS (₹)45.9939.6338.4338.1134.17358.761,597.44
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital24.5524.5124.5124.5124.511.961.96
Reserves & surplus3,3082,7932,3082,1142,030751400
Shareholders' funds (net worth)3,3322,8172,3322,1382,054753402
Secured loans0.000.000.000.000.000.000.00
Unsecured loans56.7756.6117.1519.362.880.000.02
Total debt56.7756.6117.1519.362.880.000.02
Total liabilities3,4252,8932,3652,1652,057753402
Assets
Gross block1,3671,2191,012936711652595
Net block1,038955805781595573546
Capital work in progress28410210661.6291.6914.1010.73
Investments7804780.080.080.080.080.08
Inventories692674667604516513413
Sundry debtors1,073970765807673620639
Cash & bank balances2.1371.2430230951211610.00
Loans & advances10214318213062.6915198.71
Total current assets1,8691,8581,9161,8501,7651,3991,160
Total current liabilities5004654364943821,2211,307
Net working capital1,3691,3931,4801,3561,382178(147)
Total assets3,4252,8932,3652,1652,057753402
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash71.0630128451211610.002.06
Net cash from operating activities565392414306598388195
Net cash from investing activities(570)(616)(116)(147)(122)(68.73)(50.52)
Net cash from financing activities(64.34)(6.23)(279)(388)(78.80)(214)(137)
Net change in cash(69.08)(230)17.59(228)3971067.94
Closing cash2.1371.2430230951211610.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.9%+4.5%+5.6%+1.8%+12.6%+22.6%+73.4%
EBITDA growth+13.0%+1.2%+5.0%+4.3%+4.2%+25.2%+90.5%
PBT growth+14.9%+3.6%+0.4%+11.3%+20.0%+11.9%+84.4%
Net income growth+14.9%+1.5%+0.9%+11.5%+19.1%+12.1%+60.1%
Revenue CAGR (3Y)+5.7%+4.0%+6.6%+12.0%+33.8%+1861.0%-
EBITDA CAGR (3Y)+6.3%+3.5%+4.5%+10.8%+35.5%--
Profitability & leverage
Net income margin+22.1%+20.4%+20.6%+21.6%+19.7%+18.7%+20.4%
Return on capital employed+24.0%+25.0%+27.9%+29.8%+42.2%+96.8%+185.6%
Return on net worth+18.4%+18.9%+21.1%+22.3%+29.8%+60.9%+127.8%
Debt / equity0.020.010.010.010.000.000.00
Long-term debt / equity0.020.010.010.000.000.000.00
Interest cover0.770.390.250.094.8415.707.57
Efficiency & per share
Fixed asset turnover1.972.142.342.623.123.022.87
Inventory turnover3.743.563.593.864.124.073.78
Debtors turnover2.502.752.902.923.283.002.83
EPS (₹)45.9939.6338.4338.1134.17358.761,597.44
Dividend per share (₹)5.005.0022.5042.0021.000.000.00
Book value per share (₹)271.49229.92190.35174.51167.66768.112,049.45
Want more history and ratios?
You're viewing the latest exchange-filed financials for Alivus Life Sciences Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Alivus Life Sciences Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 74.90%, foreign institutional investors hold 5.50%, domestic institutional investors hold 7.20%, retail and other public shareholders hold 12.40% of Alivus Life Sciences Limited.

Promoters: 74.90%DII (Domestic Institutional): 7.20%FII (Foreign Institutional): 5.50%Retail & Others: 12.40%
Jun 2026
QUARTER
74.90% Promoters
7.20% DII (Domestic Institutional)
5.50% FII (Foreign Institutional)
12.40% Retail & Others
Promoter holding - history
Now 74.90% · Jun 2026High 74.90% · Sep 2025Low 74.90% · Sep 2025
73%73.8%74.5%75.3%76%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 74.90%Dec 2025: 74.90%Mar 2026: 74.90%Jun 2026: 74.90%74.90%74.90%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters74.90%74.90%74.90%74.90%
Public25.10%25.10%25.10%25.10%

Charges & Borrowings Alivus Life Sciences Limited

Alivus Life Sciences Limited does not have any charges (loans) registered with the Registrar of Companies.

Employees and EPFO Compliance at Alivus Life Sciences Limited

Alivus Life Sciences Limited has a workforce of 2,021 employees as of Feb 28, 2025.

Employee count
2,021
Active EPFO establishments
1
Employee growth
5.98%
Premium access

Employee and EPFO history for Alivus Life Sciences Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Alivus Life Sciences Limited

Premium access

GST registrations and filing compliance for Alivus Life Sciences Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Alivus Life Sciences Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Alivus Life Sciences Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Alivus Life Sciences Limited

Premium access

MSME payment history for Alivus Life Sciences Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Alivus Life Sciences Limited

Premium access

Corporate group structure for Alivus Life Sciences Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Alivus Life Sciences Limited

Premium access

MCA filings and documents for Alivus Life Sciences Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Alivus Life Sciences Limited

Activity
08 Sep 2025
Alivus Life Sciences Limited last Annual general meeting of members was held on 08 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Alivus Life Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Pune.
Directors
25 Apr 2024
Savan Rashmikant Godiawala was appointed as a Director on 25 Apr 2024 & has been associated with this company since 2 years 5 months.
Directors
06 Mar 2024
Kaushikbhai Nandubhai Patel was appointed as a Director on 06 Mar 2024 & has been associated with this company since 2 years 6 months.
Directors
06 Mar 2024
Hiren Karsanbhai Patel was appointed as a Director on 06 Mar 2024 & has been associated with this company since 2 years 6 months.
Directors
21 Oct 2022
Vinod Naik was appointed as a Whole-time director on 21 Oct 2022 & has been associated with this company since 3 years 11 months.

Recent News on Alivus Life Sciences Limited

Broker’s call: Glenmark Pharma (Neutral)
21 Feb 2024 · Thehindubusinessline

Frequently Asked Questions about Alivus Life Sciences Limited

Alivus Life Sciences Limited is an active public limited company in the pharma sector based in Solapur, Maharashtra, India. It was incorporated on 23 June 2011 (15+ years old) and is registered under CIN L74900PN2011PLC139963. Listed on BSE: 543322 and NSE: GLS. The company has 2,021 employees.

Alivus Life Sciences Limited reported revenue of ₹2,551.83 Cr for FY 2025-26 (up 6.91% YoY) based on standalone financials.

The current directors of Alivus Life Sciences Limited are:

The primary industry of Alivus Life Sciences Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Alivus Life Sciences Limited is listed on both BSE (code: 543322) and NSE (symbol: GLS).

Alivus Life Sciences Limited can be reached at the registered office: Plot No 170 – 172 Chandramouli Industrial Estate Mohol Ba, Zarpeth, Solapur, Maharashtra, India – 413213, or through the website glenmarklifesciences.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available